Most men diagnosed with a localized prostate cancer (PC) undergo aggressive therapy with either radical prostatectomy (RP) or radiotherapy (EBRT) (1) . Although there are no adequately sized, completed randomized clinical trials comparing these two modalities, there are two randomized clinical trials with long-term follow-up that compared surgery to watchful waiting. These studies effectively reported conflicting results (2, 3) . Regardless, all treatments for localized PC can cause bothersome complications, including urinary, sexual, and bowel dysfunction (4) . Consequently, treatment for localized PC has come to be recognized as preference sensitive care (5) , where informed patients should make decisions after weighing the benefits and harms of the treatments.
Prior studies comparing RP and EBRT are difficult to interpret because of treatment selection bias, incomplete follow-up, variable treatment protocols, and reliance on surrogate endpoints. To better inform PC treatment decisions, the Prostate Cancer Outcomes Study (PCOS) assembled a population-based cohort of men with newly diagnosed PC in the mid-1990s (6) . By collecting extensive baseline demographic, comorbidity, tumor, and treatment data from medical records and patient surveys, PCOS was better able to control for confounding than prior observational studies. Using propensity score analyses to adjust for treatment selection bias, we compared 15-year overall and PC-specific survival for men aged 55 to 74 years with clinically localized cancer who underwent either RP or EBRT.
Methods
The PCOS cohort was assembled using the Surveillance, Epidemiology and End-Results (SEER) program, which provides information on cancer incidence, treatment, and survival for a population-based sample of about 15% of the United States. Details of the PCOS have been published elsewhere (6) . Briefly, the study used a rapid case ascertainment system to identify all men diagnosed with microscopically confirmed primary invasive adenocarcinoma of the prostate between October 1, 1994, and October 31, 1995. Patients were diagnosed in six SEER tumor registries covering the states of Connecticut, Utah, and New Mexico, and the metropolitan areas of Atlanta, Georgia; Los Angeles County, California; and King County, Washington (which includes Seattle). The institutional review board of each PCOS site approved the study. In the opinion of the institutional review boards, participating subjects provided implied informed consent by returning the 6-or 12-month survey.
The PCOS randomly sampled a total of 5672 subjects from the 11 137 eligible PC case subjects. A prespecified sampling strategy was employed that oversampled younger men, Hispanics, and blacks (to ensure a representative population of PC patients), while maintaining adequate sample size to address key research questions (6) . Sample weights were calculated as the inverse of the sampling proportions within each region-race-age group stratum.
The final PCOS study cohort was comprised of the 3533 men (62%) who completed a sociodemographic and health-related quality of life survey at 6 and/or 12 months after initial diagnosis. Of these, 3073 men (87%) had clinically localized cancer (confined to the prostate) at diagnosis. For the current analysis, we limited our study cohort to men in PCOS who were diagnosed at age 55 to 74 years with clinically localized cancer and who underwent either RP or EBRT therapy as primary treatment (with or without androgen deprivation therapy [ADT]). If patients received both RP and EBRT within the first year after diagnosis, they were classified by the treatment they received first. We identified 1655 men in the PCOS cohort meeting these inclusion criteria, of whom 1164 (70.3%) underwent RP and 491 (29.7%) underwent EBRT.
Data Collection
At the time of initial enrollment, investigators contacted patients by mail and/or telephone and requested them to complete a selfadministered survey and sign a release form allowing review of all medical records from any physicians and facilities providing care for PC. Using a standard protocol, abstractors collected information on demographic factors, diagnostic examinations, biopsy results, tumor characteristics, clinical staging, and treatment within 12 months of diagnosis.
Demographic and socioeconomic questions were used to determine race/ethnicity, employment status, educational level, household income, insurance coverage, and marital status. Additionally, we assessed comorbidity by asking about 12 medical conditions based on the Charlson comorbidity index (7, 8) .
We identified subjects with clinically localized PC based on an SEER algorithm using clinical information abstracted from medical records. The algorithm defined T1 tumors as confined to the prostate, with a normal digital rectal examination, and with no positive scans (magnetic resonance imaging, computed tomography, bone scan) or evidence of metastases. T2 tumors were defined as confined to the prostate, with abnormal or suspicious digital rectal examinations, but with no positive scans or evidence of metastases. In some cases, we were able to identify tumors as confined to the prostate but could not differentiate between T1 and T2 stage, and we thus classified these cancers as stage T1/T2.
We obtained vital status information from the SEER tumor registries in the spring of 2011, which provided follow-up information through the end of 2010, roughly 15 years after study initiation. When a subject dies, registries obtain computerized death data files from their local departments of health and/or the National Death Index, with underlying cause of death coded using established algorithms maintained by the National Center for Health Statistics (9) .
Statistical Analysis
The study used a stratified sampling strategy defined by age, race/ ethnicity, and region. With the exception of some descriptive statistics, all analyses have taken this sampling into account, using the inverse of the sample proportion for weights (the HorvitzThompson weight).
We used propensity score methodologies to reduce potential treatment selection bias (10) . We identified the baseline patient characteristics [registry, age, race, TNM classification of malignant tumors (TNM) clinical stage (11), Gleason score (12), comorbidity, diagnostic prostate-specific antigen (PSA), income, insurance, education, marital status, and employment status] thought to predict surgical treatment and estimated the propensity score for receiving RP by including these in a multivariable logistic regression model with treatment as the response variable. The predicted values from the regression model estimated the propensity (probability) of each patient for receiving RP conditional on his baseline characteristics.
Baseline patient characteristics were summarized for both groups; the between-group differences were assessed by fitting a logistic regression model using treatment as the response variable and each baseline characteristic as the covariable with and without the propensity score as an additional covariable. This analysis accounted for sampling weights.
We used multivariable proportional hazards regression models to compare overall and PC mortality for men who underwent RP or EBRT, weighted for the sampling strategy. We included the following covariables in all multivariable models (unless the effective sample size was too small for stable coefficient estimates): age at diagnosis, comorbidity score, propensity score (treated as continuous variables), race/ethnicity, educational attainment, diagnostic PSA level, Gleason score, clinical stage, and registry. We estimated adjusted hazard ratios (HRs) as the measure of treatment effect with EBRT as the reference group. We checked the proportional hazard assumption for all variables included in each model using scaled Schoenfeld residuals (13) and found no violations. For PC mortality, we also fit competing risks models (14) and noted that the conclusions based on subhazard ratios were essentially the same.
We performed additional analyses to examine the robustness of our approach using propensity scores. We fit a proportional hazards regression model using treatment as the sole covariable for subgroups defined by propensity score quintiles. We compared the treatments using propensity score-matched samples. The optimal set of matches was constructed using reweighted Mahalanobis distance matching (15, 16) . Finally, we also used the propensity score to construct the inverse probability of treatment weights (1, 17, 18) . Weights were truncated at 0.1 and 10 as discussed in Harder et al. (2, 3, 19) . Results of these three alternative analytic strategies were virtually identical to the primary propensity score analysis and are not discussed.
Because a previous trial suggested that RP did not improve survival compared with watchful waiting among men aged 65 years or older (2,4), we also estimated overall and PC mortality according to age. Randomized trials also suggested that high-risk cancers respond better to EBRT combined with ADT compared with radiation therapy alone (5, 6, 20, 21) . Therefore, we evaluated mortality for men with high-risk cancers (PSA > 10 or Gleason score ≥ 8) who received either RP or EBRT and adjuvant ADT and for men with low-risk PC (PSA < 10, Gleason ≤ 6), who were shown not to benefit from aggressive treatment in one trial (3, 6) as well as men reporting no comorbidities on their baseline survey.
All significance tests were two-sided and a P value less than .05 was considered statistically significant. All statistical analyses used R version 2.13 (R Foundation for Statistical Computing, Vienna, Austria.) with the following packages: survival for general survival analysis (R package version 2.36-14.), survey for weighted analyses (R package version 3.28-2.), cmprsk for competing risks models (R package version 2.2-2).
results
The study cohort consisted of 1655 men aged 55 to 74 years at the time of diagnosis, with clinically localized PC who underwent primary therapy with either RP (n = 1164) or EBRT (n = 491). Table 1 shows baseline patient characteristics stratified by treatment. Men who underwent RP were more likely to be aged less than 65 years, have private insurance, and have no comorbidities compared with those undergoing EBRT and less likely to be in a racial/ethnic minority group. However, after adjusting for treatment propensity scores, there were no statistically significant differences between treatment groups. Table 2 shows baseline tumor characteristics stratified by treatment. Surgical subjects were more likely to have well-differentiated tumors, but the finding was not statistically significant. Overall, 592 (35.7%) subjects had high-risk cancers, including 381 (32.7%) surgical and 211 (43.0%) EBRT subjects. No statistically significant differences existed after adjusting for propensity scores.
During the 15-year follow-up period, there were 568 deaths among our study cohort, including 104 deaths from PC. Figures 1  and 2 show unadjusted cumulative overall and PC mortality, respectively, stratified by treatment. Overall mortality, adjusted for demographic, clinical, and tumor characteristics and the propensity score and weighted for sampling strategy was statistically significantly lower for men undergoing RP compared with EBRT (HR = 0.60, 95% confidence interval [CI] = 0.53 to 0.70, P <.0001). Similarly, the adjusted hazard ratio for PC mortality was more favorable for men undergoing RP than for those receiving EBRT (HR = 0.35, 95% CI = 0.26 to 0.49, P <.0001). Results for overall and PC mortality were similar when using a competing risk analysis (data not shown). Table 3 shows that the overall and PC mortality benefits for RP compared with EBRT were consistent across all propensity quintiles. The propensity-score pair-matched analysis also showed that men undergoing RP had decreased overall (HR = 0.65, 95% CI = 0.56 to 0.75) and PC mortality (HR = 0.40, 95% CI = 0.28 to 0.56) compared with men undergoing EBRT.
We evaluated the effect of age on mortality. In multivariable survival analyses, overall and PC mortality were statistically significantly lower with RP compared with EBRT for men in both the group aged 55 to 64 years and the group aged 65 to 74 years (Table 4) .
We compared mortality outcomes for the 437 men with highrisk tumors who received either RP or combined EBRT and ADT (Table 4) . Overall, there were 162 deaths, including 37 from prostate cancer. Multivariable survival analyses showed that overall and PC mortality were statistically significantly lower in the RP group than in the combined EBRT and ADT group (Table 4) .
We also compared mortality outcomes for the 753 men with low-risk tumors (Gleason ≤ 6 and diagnostic PSA ≤ 10 ng/mL). Overall, there were 200 deaths, including 17 from prostate cancer. In multivariable survival analyses, we found a just barely statistically significant difference for overall mortality in this group but no significant difference in PC-specific mortality (Table 4.) Finally, we compared mortality outcomes for the 672 patients reporting no comorbidities on their baseline survey. Overall and PC mortality were statistically significantly lower among the men treated with RP than those treated with EBRT (Table 4) . 
Discussion
Although surgery for localized PC has been compared with watchful waiting in randomized trials (2, 3, 7, 8) , there are no published survival results from randomized trials directly comparing RP with EBRT. We used data from the population-based observational PCOS to conduct a comparative effectiveness study of RP and EBRT. Using propensity scores as covariables in survival analyses, for stratification, for matched-pair analyses, and in an inverse probability of treatment weights analyses, we consistently found that overall and prostate cancer mortality were lower after RP than after EBRT. The PCOS subjects were diagnosed in the mid-1990s when the majority of PC cases were detected with PSA screening. Only 6.3% of the subjects died from PC during 15 years of follow-up, reflecting the favorable survival associated with screen-detected localized PC (9, 22) . Subjects appear to be representative of cancer case subjects being diagnosed and treated for localized cancer during this time period. The cumulative PC mortality observed in PCOS subjects undergoing RP was 5.0%, which was just slightly lower than the 5.8% observed during a median 10-year follow-up (range = 7.3 to 12.6) in the RP arm of the PIVOT study (3, 10) . In contrast, the 15-year PC mortality in the prostatectomy arm of the SPCG-4 trial was 14.6% (2, 13) . This higher proportion is expected because just 12.4% of cancers in SPCG-4 were diagnosed at stage T1c.
The cumulative PC mortality observed in subjects undergoing EBRT was 17.2%, which is comparable with the 18% reported in abstract findings by the Scandinavian prospective randomized trial comparing external beam radiotherapy vs watchful waiting in early prostate cancer (14, 23) . The Scandinavian study enrolled 214 subjects from 1986 to 1997 and had a minimum follow up of 16 years. * EBRT = external beam radiotherapy; PSA = prostate-specific antigen; RP = radical prostatectomy.
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A more contemporary randomized trial of EBRT plus 4 months of ADT vs EBRT alone reported 10-year PC mortality in the study arms of 4% and 8%, respectively (15, 16, 20) .
The survival advantage associated with RP needs to be interpreted cautiously. The outcomes reflect treatment modalities and approaches being offered in the mid-1990s and might be less applicable today, particularly in the case of EBRT for high-risk disease. More recent studies have shown that men with high-risk PC undergoing EBRT benefit substantially from prolonged (6 months to 3 years) courses of ADT (21, 24, 25) . When we looked at the subset of men with high-risk PC who underwent RP or EBRT and ADT, we still found a statistically significant survival advantage with RP. However, this could reflect residual selection bias in the EBRT group due to unmeasured confounders or inadequate sample size. Another possibility is that the findings represent a true survival advantage.
Recent trial reports indicate that men with low-risk tumor features are unlikely to benefit from aggressive curative therapies (3, 20) . Observational data suggest that these men can be safely managed with active surveillance, with treatment avoided in the absence of clinical, biochemical, or histological evidence of disease progression (26) (27) (28) . Indeed, when we limited our analysis to men with lowrisk cancers, the treatment benefit associated with RP was markedly Figure 2 . Prostate cancer-specific cumulative mortality by treatment in men with clinically localized prostate cancer. The two-sided log-rank test reveals that the two curves are statistically significantly different (P <.001). * A proportional hazards regression model using treatment as the sole covariable for subgroups defined by propensity score quintiles was used to test the robustness of the propensity score approach. All statistical tests were two-sided. CI = confidence interval; EBRT = external beam radiotherapy; HR = hazard ratio; RP = radical prostatectomy.
diminished. However, without an active surveillance control group, we cannot determine the absolute benefit of treatment or whether EBRT is better than no treatment for men with low-risk PC. We found that RP was better than EBRT for men both older and younger than 65 years at the time of treatment, although the benefit was markedly attenuated in the older age group. The PIVOT trial also found no interaction between treatment arm and age. The SPCG-4 study found a survival benefit for receiving RP compared with watchful waiting only for men aged less than 65 years; however, these subjects had relatively more advanced stage clinically detected cancers (3) . Secular trends could also affect the generalizability of our results. For example, patients sometimes underwent pelvic lymph node dissection before radiation in the mid-1990s, either in the setting of aborted radical prostatectomy or for staging before EBRT. In an effort to control for this, we performed a sensitivity analysis in which we excluded the 12 patients in the radiation group (2.4%) who underwent pelvic lymph node dissection before EBRT. This did not statistically significantly alter our findings (data not shown). In addition, surgical and radiation techniques have evolved substantially over the past two decades. However, the advent of higher prostate dosing and three-dimensional conformal and intensity-modulation radiation therapy techniques has likely advanced radiation techniques to a greater degree than surgical advances (29) . Conversely, patient selection has improved, particularly for men with limited life expectancy who are less likely to be treated surgically (1) .
We recognize that residual treatment selection bias could have led to spurious estimates of survival differences. We attempted to address this bias with propensity score analyses based on the characteristics most strongly associated with treatment selection. We found statistically significantly decreased hazard ratios for PC mortality when using propensity scores as a covariable, when stratifying by propensity-score quintiles, when matching by propensity score, and when using an inverse probability of treatment weights approach. However, an SEER-Medicare analysis of men with localized PC used similar techniques in comparing overall survival for men receiving aggressive vs conservative treatment (30) and was criticized for inadequate adjustment (31) . By performing medical record abstractions and patient surveys, we included more detailed information on baseline covariables than can be obtained from claims data alone. Nonetheless, we may have missed capturing potentially important prognostic information, such as the number of positive biopsy cores and extent of biopsy tumor involvement.
Although we used a comorbidity score based on the Charlson index (7), this is a relatively crude measure. We may have failed to accurately characterize the severity of baseline comorbid conditions or suboptimally weighted these conditions, resulting in residual confounding. Since the initiation of the PCOS study, researchers have developed tools that not only better capture the severity of a particular condition but also are specifically designed to predict other-cause mortality in localized prostate cancer (32) . Some authors have even suggested that the weighting of conditions in the original Charlson index could be changed to better predict outcomes in prostate cancer (33) . It is possible that we missed other important factors, such as frailty or functional status, which may have resulted in residual bias. Indeed, we still found a survival benefit for RP even among men with no documented baseline comorbidities. Population-based observational data on men diagnosed with localized PC in the mid-1990s suggest that treatment with RP was associated with a statistically significant reduction in overall and PC-specific mortality when compared with EBRT. The benefit was most notable in healthier men, those aged less than 65 years, and men with higher-risk cancers. Possible explanations include residual selection bias or a true survival advantage for RP in this cohort. In the absence of randomized controlled trials, our data provide the best estimate for the long-term comparative effectiveness of RP and EBRT. Further comparative effectiveness research is needed to compare treatment outcomes among more contemporary cohorts of men with localized PC.
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